On June 6, 2012, Germany’s Merck Serono, a division of Merck, announced a partnership with India’s Dr. Reddy’s Laboratories Inc. to develop a portflolio of oncology biosimilars, primarily focused on monoclonal antibodies. Under the agreement, Dr. Reddy’s will lead early product development up to the completion of phase I trials, after which Merck Serono will take over phase III manufacturing and development. Merck Serono will be responsible for global commercialization outside the United States and in select emerging markets. The parties will co-commercialize the products in the U.S. on a profit-sharing basis.
A copy of the Merck Serono press releases announcing the partnership may be found here.